Literature DB >> 6184152

Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies.

F J Primus, K D Newell, A Blue, D M Goldenberg.   

Abstract

Murine monoclonal antibodies against carcinoembryonic antigen (CEA) derived from a colonic tumor were analyzed by radioimmunoassay for reactivity with CEA and the CEA-related antigens, meconium antigen (MA) and nonspecific cross-reacting antigen. Antibody-antigen binding profiles revealed three classes of hybridomas. The Class I antibody, NP-1, recognized an epitope shared among all three antigens, and its affinity for CEA and MA was high but low for nonspecific cross-reacting antigen. The Class II antibodies reacted with sites shared between CEA and MA, while those of the Class III type only bound CEA. The Class III antibody, NP-4, bound less than 50% of the CEA molecules recognized by goat specific anti-CEA antibody and the other classes of monoclonal antibodies. Two Class II antibodies, NP-2 and NP-3, bound similar amounts of CEA and MA with moderate but different affinities for CEA. Studies using labeled monoclonal antibodies for CEA epitope blocking revealed that NP-2 and NP-3 recognize two separate epitopes on CEA within the Class II category. Thus, monoclonal antibodies to CEA can differentiate at least four antigenic sites on colonic cancer CEA. One is shared by CEA, MA, and nonspecific cross-reacting antigen; two others are shared by CEA with MA; and a fourth appears specific for a subpopulation of CEA molecules.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184152

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Epitope distribution and immunochemical characterization of nucleolar phosphoprotein C23 using ten monoclonal antibodies.

Authors:  J W Freeman; A Chatterjee; B E Ross; H Busch
Journal:  Mol Cell Biochem       Date:  1985-09       Impact factor: 3.396

2.  Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells.

Authors:  M J Mattes; K O Lloyd; J L Lewis
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli.

Authors:  S Cabilly; A D Riggs; H Pande; J E Shively; W E Holmes; M Rey; L J Perry; R Wetzel; H L Heyneker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 4.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Preliminary findings in the evaluation of hepatic malignancies by radioimmunodetection, X-ray computed tomography, and magnetic resonance imaging.

Authors:  F H DeLand; A Lieber; M D Ram; D M Goldenberg
Journal:  Eur J Nucl Med       Date:  1986

6.  Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor.

Authors:  O C Boerman; R M Sharkey; G Y Wong; R D Blumenthal; R L Aninipot; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Variations in radioimmunoscintigraphic detection of tumor showed by five monoclonal antibodies to carcinoembryonic antigen.

Authors:  K Kohno; K Nakata; Y Kusumoto; N Ishii; T Kohji; Y Matsuoka; S Nishi; S Nagataki
Journal:  Ann Nucl Med       Date:  1991-07       Impact factor: 2.668

8.  Diverse characteristics of 111In labelled anti-CEA monoclonal antibodies for tumour immunoscintigraphy: radiolabelling, biodistribution and imaging studies in mice with human tumour xenografts.

Authors:  M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1987

Review 9.  Monoclonal antibodies in imaging and therapy of colorectal cancer.

Authors:  M K Lange; E W Martin
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

10.  Localization of an anti-CEA monoclonal antibody in colo-rectal carcinoma xenografts.

Authors:  M V Pimm; N C Armitage; A C Perkins; W Smith; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.